Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.
Reinhard Dummer
,
Shahneen Sandhu
,
Wilson H Miller
,
Marcus O Butler
,
Matthew H Taylor
,
Lucie Heinzerling
,
Christian U Blank
,
Eva Muñoz Couselo
,
Howard A Burris
,
Michael A Postow
,
Bartosz Chmielowski
,
Mark R Middleton
,
Carola Berking
,
Jessica C Hassel
,
Anja Heike Gesierich
,
Cornelia Mauch
,
Joseph F Kleha
,
Anna Polli
,
Allison S Harney
,
Alessandra di Pietro
,
Paolo A Ascierto
More about this publication
Future oncology (London, England)
Volume
22
Issue nr.
9
Pages
995-1013
Publication date
01-04-2026
Full text links
Publisher website (DOI)
10.1080/14796694.2026.2643481
Europe PubMed Central
41914670
Pubmed
41914670